Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
Aduhelm Recent News
FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch